Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gretchen L Sacha

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Chest|July 21, 2023
Optimizing Vasopressin Use and Initiation Timing in Septic Shock: A Narrative ReviewGretchen L Sacha, Seth R Bauer
Cleveland Clinic Journal of Medicine|May 16, 2020
Antivirals for COVID-19Pavithra Srinivas, Gretchen L Sacha, Christine Koval
Critical Care Medicine|September 15, 2022
The authors replyGretchen L Sacha, Lu Wang, Seth R Bauer
Pharmacotherapy|January 16, 2019
Vasoactive Agent Use in Septic Shock: Beyond First-Line RecommendationsGretchen L Sacha, Seth R Bauer, Ishaq Lat
Annals of Translational Medicine|November 22, 2016
Did the beneficial renal outcomes with vasopressin VANISH?Gretchen L Sacha, Simon W Lam, Seth R Bauer
The Annals of Pharmacotherapy|November 5, 2019
Mortality, Morbidity, and Costs After Implementation of a Vasopressin Guideline in Medical Intensive Care Patients With Septic Shock: An Interrupted Time Series AnalysisSeth R Bauer, Gretchen L Sacha, Anita J Reddy
Pharmacotherapy|June 8, 2018
Safe Use of Vasopressin and Angiotensin II for Patients with Circulatory ShockSeth R Bauer, Gretchen L Sacha, Simon W Lam
Shock (Augusta, Ga.)|February 8, 2021
Author's Response: Abrupt Discontinuation Versus Down-Titration of Vasopressin in Patients Recovering from Septic ShockSimon W Lam, Gretchen L Sacha, Seth R Bauer
Current Opinion in Critical Care|June 8, 2018
Vasodilatory shock in the ICU and the role of angiotensin IIBrett J Wakefield, Gretchen L Sacha, Ashish K Khanna
Journal of Thrombosis and Thrombolysis|June 4, 2016
The use of anti-factor Xa monitoring in a selection of patients receiving enoxaparin at a large academic medical centerGretchen L Sacha, Katie M Greenlee, Jeffrey M Ketz
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Chest|July 21, 2023
Optimizing Vasopressin Use and Initiation Timing in Septic Shock: A Narrative ReviewGretchen L Sacha, Seth R Bauer
Cleveland Clinic Journal of Medicine|May 16, 2020
Antivirals for COVID-19Pavithra Srinivas, Gretchen L Sacha, Christine Koval
Critical Care Medicine|September 15, 2022
The authors replyGretchen L Sacha, Lu Wang, Seth R Bauer
Pharmacotherapy|January 16, 2019
Vasoactive Agent Use in Septic Shock: Beyond First-Line RecommendationsGretchen L Sacha, Seth R Bauer, Ishaq Lat
Annals of Translational Medicine|November 22, 2016
Did the beneficial renal outcomes with vasopressin VANISH?Gretchen L Sacha, Simon W Lam, Seth R Bauer
The Annals of Pharmacotherapy|November 5, 2019
Mortality, Morbidity, and Costs After Implementation of a Vasopressin Guideline in Medical Intensive Care Patients With Septic Shock: An Interrupted Time Series AnalysisSeth R Bauer, Gretchen L Sacha, Anita J Reddy
Pharmacotherapy|June 8, 2018
Safe Use of Vasopressin and Angiotensin II for Patients with Circulatory ShockSeth R Bauer, Gretchen L Sacha, Simon W Lam
Shock (Augusta, Ga.)|February 8, 2021
Author's Response: Abrupt Discontinuation Versus Down-Titration of Vasopressin in Patients Recovering from Septic ShockSimon W Lam, Gretchen L Sacha, Seth R Bauer
Current Opinion in Critical Care|June 8, 2018
Vasodilatory shock in the ICU and the role of angiotensin IIBrett J Wakefield, Gretchen L Sacha, Ashish K Khanna
Journal of Thrombosis and Thrombolysis|June 4, 2016
The use of anti-factor Xa monitoring in a selection of patients receiving enoxaparin at a large academic medical centerGretchen L Sacha, Katie M Greenlee, Jeffrey M Ketz
Pageof 6